Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KMN-159,Collagen
Therapeutic Area : Musculoskeletal
Study Phase : Preclinical
Sponsor : NIDCR
Deal Size : $1.7 million
Deal Type : Funding
Cayman Receives Grant to Evaluate Use of KMN-159 to Accelerate Dental Implant Osseointegration
Details : The grant will be used to explore Cayman’s patented small molecule bone repair agent KMN-159 as the active pharmaceutical ingredient (API) in a drug-device combination to improve the mechanical anchorage of dental titanium implants into the jawbone.
Brand Name : KMN-159
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 16, 2021
Lead Product(s) : KMN-159,Collagen
Therapeutic Area : Musculoskeletal
Highest Development Status : Preclinical
Sponsor : NIDCR
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : Antibody
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : SBIR
Deal Size : Undisclosed
Deal Type : Funding
Cayman Receives SBIR Grant for Alzheimer’s Research
Details : The funding will be used to develop an assay platform and novel antibodies to support the treatment, prevention, and early diagnosis of Alzheimer’s disease and other tauopathies.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 08, 2020
Lead Product(s) : Antibody
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : SBIR
Deal Size : Undisclosed
Deal Type : Funding
LOOKING FOR A SUPPLIER?
Reset All
